Based on successful completion of pre-market development, our novel ophthalmic compound is ready for clinical testing (Phase II) in a patient population. This is the final clinical hurdle before movement to market. However, to undertake such testing, we are required to generate pharmacokinetic data to obtain pharmaceutical registration and approval by the relevant regulatory bodies (e.g. TGA). We are therefore applying for DTF funding to undertake this work and, in doing so, establish the facilities at UC to support other such projects during drug development and commercialisation.
|Effective start/end date||1/11/21 → 31/03/24|
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.